PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final ...
PITTSBURGH, Pa. Mylan Pharmaceuticals has received tentative approval from the Food and Drug Administration for a generic version of Lamictal. Lamictal, by GlaxoSmithKline is used to treat epilepsy ...
Lamotrigine Tablets are the generic version of GlaxoSmithKline's Lamictal (R) Tablets, which had U.S. sales of approximately $1.97 million for the 12 months ending Sept. 30, 2007. Mylan Inc. is one of ...
> The FDA gave a tentative nod to Mylan's generic version of the GlaxoSmithKline seizure and bipolar drug Lamictal. Release > The UK's National Institute for Clinical Excellence is expected to ease ...
LOS ANGELES -- The FDA's warning about arrhythmia risk with lamotrigine (Lamictal) based on in vitro data wasn't borne out in observational cohorts of people with epilepsy, although the risk did ...
The anticonvulsant medication lamotrigine can cause the rare but serious immune system reaction hemophagocytic lymphohistiocytosis (HLH), the US and Food and Drug Administration said today in a safety ...
The FDA on Wednesday updated its warning about potential increased arrhythmia risk in people with cardiac disease who are taking the seizure and mental health drug lamotrigine (Lamictal) with new data ...
NEW YORK (MedscapeWire) May 23 — Lamotrigine (Lamictal) has distinct and perhaps complementary mood-stabilizing effects for the treatment of bipolar disorder, according to presentations on May 20 and ...
Lamotrigine is indicated as monotherapy or adjunctive therapy for epilepsy and for use as maintenance treatment in patients with bipolar I disorder. Following a review of in vitro study findings, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback